Juvenile dermatomyositis

While in other diseases the emergence of biologic drugs has changed the prognosis, an optimal biologic drug for the treatment of JDM has not yet been found. The most commonly used are rituximab, which acts mainly against B lymphocytes, or anti-TNF-alpha drugs such as infliximab or adalimumab.

The dose and route of administration depend on each drug, and are determined by clinical trials in other diseases.

The mechanism of action and side effects of each of these drugs is beyond the scope of this chapter as they are rarely used treatments for this disease.